HRT and Sexual Health

Educational only. Not medical advice. Sexual health concerns during menopause have medical, psychological, and relational dimensions. A clinician with menopause expertise can help identify the primary drivers and appropriate treatment.

Sexual health is the menopausal symptom women are most reluctant to raise with their clinician, most frustrated by when they do, and most likely to suffer in silence over for years. It is also the symptom where the cause-and-treatment landscape is most complex, because menopause affects sexuality through at least four overlapping mechanisms - and treating only one while ignoring the others produces incomplete results.

Roughly 50 to 70% of postmenopausal women report some degree of sexual dysfunction. For many, it is the symptom that most affects their relationships and self-perception. It deserves the same clinical seriousness as hot flashes and bone health.

• Menopause affects sexuality through four mechanisms: decreased desire (hormonal), impaired arousal (vascular/neurological), pain from vaginal atrophy (tissue), and psychological/relational factors
• Vaginal estrogen is the most effective treatment for pain during intercourse from GSM and should be offered to every woman who reports this symptom
• Low-dose vaginal estrogen is safe for many women who cannot use systemic HRT, including some breast cancer survivors
• Testosterone is evidence-based for HSDD (low desire causing distress) but only for one indication - it is not a general sexual enhancement
• The psychological and relational dimensions are real and may need their own attention alongside hormonal treatment
• Lubricants and moisturizers are not substitutes for vaginal estrogen when tissue atrophy is the problem - they manage symptoms without treating the cause

Desire (libido). Estrogen and testosterone both contribute to sexual desire. Both decline during the menopausal transition. The effect varies enormously - some women notice minimal change, others experience a fundamental shift in their relationship to sexuality. Fatigue from sleep disruption, mood changes, and body image shifts compound the hormonal effect.

Arousal. Genital arousal depends on blood flow, nerve sensitivity, and tissue health - all of which are estrogen-dependent. Reduced clitoral engorgement, decreased vaginal lubrication, and slower arousal response are physiological changes, not evidence of psychological disinterest. The brain can want sex while the body does not respond the way it used to. This mismatch is distressing and frequently misunderstood.

Pain (dyspareunia). Vaginal atrophy from estrogen loss thins the vaginal walls, reduces elasticity, decreases lubrication, and shifts the vaginal pH. The result: intercourse that was previously comfortable becomes painful. The pain creates anticipatory anxiety, which further inhibits arousal, which worsens dryness, which increases pain. This cycle escalates and can make penetrative intercourse impossible without treatment.

Psychological and relational. Body image changes during menopause. Relationship dynamics shift. The loss of spontaneous desire can create feelings of inadequacy or guilt. Partners may interpret decreased desire personally. These dimensions do not respond to estrogen - they respond to communication, counseling, and reframing expectations.

For pain (GSM/vaginal atrophy). Vaginal estrogen is first-line. It restores tissue thickness, elasticity, lubrication, and pH. Improvement begins within weeks and continues over months. Low-dose vaginal estrogen (Vagifem/Yuvafem, Estring, Imvexxy) is safe for many women who cannot use systemic HRT. Over-the-counter moisturizers (Replens, Hyalo GYN) provide interim relief and complement vaginal estrogen but do not treat the underlying atrophy. Lubricants during intercourse reduce friction but are symptomatic management, not treatment. Pelvic floor physical therapy can address associated pelvic floor tension and pain.

For desire (HSDD). Systemic HRT may improve desire by resolving the fatigue, mood changes, and sleep disruption that suppress it. If desire does not improve with adequate systemic HRT, testosterone therapy is the evidence-based pharmacological option for HSDD (see the testosterone for women treatment page). Flibanserin (Addyi) and bremelanotide (Vyleesi) are FDA-approved for premenopausal HSDD - their use in postmenopausal women is off-label with limited data.

For arousal. Estrogen restoration improves genital blood flow and nerve sensitivity. Clitoral suction devices (Eros device, FDA-cleared) can enhance arousal mechanically. Adequate foreplay and arousal time - the physiological arousal timeline shifts during menopause and may require adaptation by both partners.

For psychological/relational factors. Individual therapy or couples counseling. Sex therapy with a certified sex therapist (AASECT directory). Reframing expectations about what sex looks and feels like in this life stage. Communication strategies with partners.

If sex is painful, you do not have to accept it. Vaginal estrogen works. If desire has disappeared, it may be hormonal and treatable. If your relationship is strained by sexual changes, a therapist who specializes in sexual health can help. If your clinician dismisses your sexual concerns or tells you this is “just part of aging,” find a clinician who takes it seriously.

Sexual health is health. It deserves clinical attention, not embarrassment.

What Partners Need To Understand

Sexual changes during menopause happen to both people in a relationship, even though only one body is going through the transition. Partners who do not understand the physiological basis for decreased desire, slower arousal, and pain can internalize the changes as rejection. This creates a destructive cycle: she feels guilty about the changes, he feels unwanted, both avoid the conversation, intimacy disappears.

The information that changes this dynamic: decreased desire is not about attraction. It is about estrogen and testosterone levels affecting the neurochemistry of wanting. Slower arousal is not about interest. It is about reduced blood flow and nerve sensitivity in genital tissue. Pain during intercourse is not about willingness. It is about tissue atrophy that has a medical treatment. All of these are physiological changes with medical solutions, not relationship failures.

If your partner will read one thing, make it the explanation of the four mechanisms. Understanding that these are medical problems with medical treatments reframes the conversation from blame to teamwork.

Beyond Penetrative Sex

Menopause is an opportunity to expand the definition of satisfying sex beyond penetrative intercourse. When penetration is painful (even temporarily, while vaginal estrogen restores tissue), maintaining intimacy through other forms of physical connection prevents the avoidance pattern from taking hold. Outercourse, oral sex, manual stimulation, sensual massage, and simply maintaining physical touch and affection all preserve the intimacy that penetrative pain threatens.

A sex therapist (find AASECT-certified therapists at aasect.org) can help couples navigate this transition with specific strategies rather than general advice. This is not a sign that your relationship is broken. It is a sign that you are adapting to a physiological change, which is exactly what adults do.

• I am experiencing pain during sex - can we start vaginal estrogen?
• My desire has significantly decreased - is this hormonal, and what are my treatment options?
• Is testosterone appropriate for my situation?
• Given my breast cancer history (if applicable), is vaginal estrogen safe for me?
• Can you refer me to a pelvic floor therapist or sex therapist?